Targazyme Gets Funding for Trial Testing TZ101 for Erectile Dysfunction in PC Patients

Targazyme Gets Funding for Trial Testing TZ101 for Erectile Dysfunction in PC Patients
Targazyme has been granted an award from the The Sexual Medicine Society of North America that will fund a clinical trial testing the company's stem cell-based product TZ101 to reverse erectile dysfunction in prostate cancer patients. The study will be conducted at The University of Texas Health Science Center. Erectile dysfunction is a common complication of radical prostate cancer treatments. For men who receive either surgery or radiation therapy, nerve and vascular damage will make 60% experience erectile dysfunction at 2 years. By 15 years, up to 80% of men may have this complication. Mesenchymal stem cells (MSCs) can be used as a post-treatment strategy to repair tissue damage, and have shown promise in regenerating nerves and vascular tissues in men with erectile dysfunction. MSCs are stem cells that can give rise to different cell types — including bone, cartilage, muscle, and fat cells — and secrete factors that help regenerate other tissues. They can be isolated from different types of tissues, including bone marrow, adipose tissue, tooth pulp, and placenta/umbilical cord blood. However, using MSCs for reversing erectile dysfunction requires that cells are inserted into the corpus cavernosum — the tissue surrounding the urethra in the penis — so they can effectively secrete factors that accelerate tissue regeneration and restore erectile function. To address that, Targazyme first treats MSCs with TZ101, which adds sugar molecules to the cells' surface and creates a complex with the ability to bind certain adhesion molecules highly prevalent in conditions of tissue damage an
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *